autologous alpha-PNE switchable CAR T cells CLBR001 and CD19-specific adapter molecule SWI019

A combination of CLBR001, a preparation of autologous T lymphocytes that has been genetically engineered to express a switchable, alpha-peptide neo-epitope (PNE) chimeric antigen receptor (CAR) with a binding domain that can recognize a 14 aa peptide epitope, or PNE, of an antigen-specific adapter molecule, and SWI019, a preparation of adapter molecules consisting of an antibody fragment (Fab) targeting CD19 linked to a PNE recognizable by CLBR001, with potential immunomodulating and antineoplastic activities. Upon administration of autologous alpha-PNE switchable CAR T cells CLBR001 and CD19-specific adapter molecule SWI019, the Fab moiety of SWI019 targets and binds to tumor cells expressing CD19, and the PNE of SWI019 binds to the binding domain of CLBR001, thereby activating CLBR001. This induces selective toxicity in and causes lysis of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.